Form 4: Tvardi Therapeutics Executive Granted Stock Options

Stephen Paul O'Brien, Principal Accounting Officer of Tvardi Therapeutics, received employee stock options for 7,213 shares on April 17, 2025, vesting over four years.

Summary

• Stephen Paul O'Brien, the Principal Accounting Officer of Tvardi Therapeutics, Inc., was granted employee stock options on April 17, 2025.
• The options grant him the right to buy 7,213 shares of common stock at an exercise price of $17.04 per share.
• 25% of the options will vest on April 17, 2026, with the remaining balance vesting in equal monthly installments over the subsequent 36 months, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Risks

• The value of the options is dependent on the future performance of Tvardi Therapeutics' stock.
• If the stock price remains below the exercise price of $17.04, the options will have no intrinsic value.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract, retain, and incentivize key employees.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 25% after one year followed by monthly installments over three years is a typical vesting arrangement.
• Comparable companies such as Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the executive to contribute to the company's long-term success.
• The executive benefits from the potential upside of the company's stock performance.

Key Dates

Keywords

stock options, Tvardi Therapeutics, executive compensation, Stephen Paul O'Brien, vesting, Form 4